Raydiant Oximetry, a clinical-stage medical device company committed to improving health outcomes during childbirth, has received a new round of investment with participation from renowned women's health fund SteelSky Ventures. In this $5 million Series A2 funding round, SteelSky Ventures partnered with other notable venture capital funds focused on women's health, including deal lead Avestria Ventures, with participation from Rhia Ventures and FemHealth Ventures.

Raydiant Oximetry is a venture-backed, clinical-stage company dedicated to improving outcomes for mothers and babies during childbirth. The company has developed an innovative technology, LUMERAH™, a low-cost, non-invasive sensor that monitors fetal oxygenation during labor, with the aim to better identify fetal distress and reduce the rate of medically unnecessary C-sections. LUMERAH™ is an investigational medical device that is not currently approved for commercial sale.